2013
Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C. Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal Of The National Cancer Institute 2013, 105: 1332-1334. PMID: 23958736, PMCID: PMC3888280, DOI: 10.1093/jnci/djt204.Peer-Reviewed Original ResearchConceptsCYP2D6 genotypeCYP2D6 metabolic phenotypeBreast cancer patientsMetabolic phenotypeAnti-estrogen tamoxifenCancer clinical trialsCancer patientsClinical trialsTumor alterationsGermline DNAConflicting resultsPatientsTumorsTissue sourcesGenotype association studiesConcordanceGenotypesPhenotypeAssociation studiesFFPETTamoxifenEndoxifenWBCCYP2D6Trials
2003
Molecular profiles of invasive mucinous and ductal carcinomas of the breast a molecular case study
Pusztai L, Sotiriou C, Buchholz TA, Meric F, Symmans WF, Esteva FJ, Sahin A, Liu ET, Hortobagi GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast a molecular case study. Cancer Genetics 2003, 141: 148-153. PMID: 12606133, DOI: 10.1016/s0165-4608(02)00737-9.Peer-Reviewed Original ResearchConceptsExpression profilingComprehensive genetic analysisExpression of enzymesCDNA microarrayGenetic analysisMolecular case studyExpression profilesInhibitory genesNovel pathwayTumor phenotypeMolecular profileTherapeutic targetPhenotypeTarget therapeuticsBilateral cancerHistologic subclassificationDuctal carcinomaDifferent histologyProfilingHuman backgroundInvasive tumorsMucin productionCellular infiltrationMucinous phenotypeMolecular classification